Emergency Extraction of a Draining Thrombus with ongoing Resuscitation
Parsch, W; Erdin, P; Welker, J; Geise, A; Ficker, JH PNEUMOLOGIE. 2020; 74: S33-S34.
COVID-19 treatment by anti-coagulation: anti-thrombotic and anti-inflammatory?
Paar, V; Wernly, B; Zhou, Z; Motloch, LJ; Hoppe, UC; Egle, A; Lichtenauer, M WIEN KLIN WOCHENSCHR. 2020; 132: S217-S217.
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study
Gianni, L; Huang, CS; Egle, D; Bermejo, B; Zamagni, C; Thill, M; Anton, A; Zambelli, S; Bianchini, G; Russo, S; Ciruelos, E; Greil, R; Semiglazov, V; Colleoni, M; Kelly, C; Mariani, G; Del Mastro, L; Maffeis, I; Valagussa, P; Viale, G CANCER RES. 2020; 80(4):
REACHAUT: Real-world study of first-line (1L) ribociclib (RIB) plus endocrine therapy (ET) in HR+, HER2-metastatic breast cancer (MBC)
Singer, CF; Egle, D; Greil, R; Ohler, L; Petru, E; Suppan, C; Marhold, M; Pfeiler, G; Brunner, C; Tinchon, C; Halper, S; Galid, A; Pluschnig, U; Haslbauer, F; Hubalek, M; Redl, A; Flatschacher, J; Hennebelle, M; Mraz, B; Bartsch, R ANN ONCOL. 2020; 31: S77-S78.
Prognosis of triple negative metastatic breast cancer (MBC): Results from the AGMT_MBC-Registry
Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Tinchon, C; Fuchs, D; Balic, M; Heibl, S; Rumpold, H; Egle, D; Zabernigg, AF; Singer, CF; Andel, J; Hubalek, M; Knauer, M; Greil, R CANCER RES. 2020; 80(4):
Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB)
Murthy, R; Loi, S; Okines, A; Paplomata, E; Hamilton, E; Hurvitz, S; Lin, N; Borges, V; Abramson, VG; Anders, C; Bedard, PL; Oliveira, M; Jakobsen, E; Bachelot, T; Shachar, SS; Mueller, V; Braga, S; Duhoux, FP; Greil, R; Cameron, D; Carey, L; Curigliano, G; Gelmon, K; Hortobagyi, G; Krop, I; Loibl, S; Pegram, M; Slamon, D; Palanca-Wessels, MC; Walker, L; Feng, WT; Winer, E CANCER RES. 2020; 80(4):
Landscape of HER2-low metastatic breast cancer (MBC): Results from the AGMT-MBC-Registry
Gampenrieder, SP; Rinnerthaler, G; Petzer, A; Tinchon, C; Fuchs, D; Balic, M; Heibl, S; Rumpold, H; Egle, D; Zabernigg, AF; Singer, CF; Andel, J; Hubalek, M; Knauer, M; Greil, R CANCER RES. 2020; 80(4):
Hospitalizations and clinical outcome in metastatic colorectal cancer during regorafenib or TAS-102 therapy
Huemer, F; Piringer, G; Schlintl, V; Hackl, H; Rinnerthaler, G; Thaler, J; Greil, R; Weiss, L ONCOL RES TREAT. 2020; 43(SUPPL 4): 128-128.
Changes in the time to adjuvant chemotherapy start over the past 10 years and correlation with outcome in early breast cancer patients
Hofer, S; De Pellegrin, L; Weiss, R; Zapf, K; Gampenrieder, SP; Hauser-Kronberger, C; Reitsamer, R; Greil, R; Rinnerthaler, G ONCOL RES TREAT. 2020; 43(SUPPL 4): 161-161.
KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P plus C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Harrington, KJ; Rischin, D; Greil, R; Soulieres, D; Tahara, M; Castro, G; Psyrri, A; Baste, N; Neupane, PC; Bratland, A; Fuereder, T; Hughes, BGM; Mesia, R; Ngamphaiboon, N; Rordorf, T; Ishak, WZW; Zhang, YY; Gumuscu, B; Swaby, RF; Burtness, B J CLIN ONCOL. 2020; 38(15):